Parkinson’s Disease Biomarkers: Perspective from the NINDS Parkinson’s Disease Biomarkers Program
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's Disease Biomarker Program (PDBP) and other mechanisms, no single PD marker or set of markers are ready for clinical use. Here we discuss the current state of biomarker discovery for platforms relevant to PDBP. We discuss the role of the PDBP in PD biomarker identification and present guidelines to facilitate their development. These guidelines include: harmonizing procedures for biofluid acquisition and clinical assessments, replication of the most promising biomarkers, support and encouragement of publications that report negative findings, longitudinal follow-up of current cohorts including the PDBP, testing of wearable technologies to capture readouts between study visits and development of recently diagnosed (de novo) cohorts to foster identification of the earliest markers of disease onset.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
Self-citationProtein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867
Doty, R. L., Shaman, P., & Dann, M. (1984) · Physiology & Behavior · doi:10.1016/0031-9384(84)90269-5 · Cited by 1,854
The Existence of Publication Bias and Risk Factors for Its Occurrence
Dickersin, K. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03440100097014 · Cited by 1,417
JENKINSON, C., FITZPATRICK, R., PETO, V., GREENHALL, R., & HYMAN, N. (1997) · Age and Ageing · doi:10.1093/ageing/26.5.353 · Cited by 1,321 · cited 1×
“Patient-reported outcomes PDQ-39 Specific to PD, widely used and patient selfadministered, progression monitor for overall quality of life Difficult to determine index score without specific calculations Jenkinson et al. (1997) [37]”
BackgroundHughes, A. J., Ben-Shlomo, Y., Daniel, S. E., & Lees, A. J. (1992) · Neurology · doi:10.1212/wnl.42.6.1142 · Cited by 1,313
Mortality in Parkinson's disease: A systematic review and meta‐analysis
Macleod, A. D., Taylor, K. S. M., & Counsell, C. E. (2014) · Movement Disorders · doi:10.1002/mds.25898 · Cited by 328
Cited by
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases
Espay, A. J., Vizcarra, J. A., Marsili, L., Lang, A. E., Simon, D. K., Merola, A., Josephs, K. A., Fasano, A., Morgante, F., Savica, R., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000006926 · Cited by 274
“A cognitive dissonance in research on biomarkers and diseasemodifying treatments for Parkinson disease (PD) and Alzheimer disease (AD) is the dual acceptance of 2 opposite tenets: that their clinical heterogeneity reflects several diseases subsumed within each and that we are on the verge of finding the set of perfect…”
BackgroundDementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Jellinger, K. A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1821-9 · Cited by 264
Proteomic analysis of urinary extracellular vesicles reveal biomarkers for neurologic disease
Wang, S., Kojima, K., Mobley, J. A., & West, A. B. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.021 · Cited by 145
Self-citationStudy of blood linear RNA nominates CD55 and DLD as early-stage biomarkers for Parkinson's disease
Beric, A., Sahin, S., Sanchez, S., Yang, Z., Kumar, R., Alfradique-Dunham, I., Sanford, J., Western, D., Phillips, B., Budde, J. P., et al. (2026) · Brain · doi:10.1093/brain/awag014 · Cited by 2
“11,20,24,25 The publicly available datasets, PDBP, PPMI and BioFIND, were accessed through the Accelerating Medicines Partnership Parkinson’s Disease (AMP-PD) Knowledge Portal.”
Metadata
- Authors
- Gwinn, K., David, K. K., Swanson-Fischer, C., Albin, R., Hillaire-Clarke, C. S., Sieber, B.-A., Lungu, C., Bowman, F. D., Alcalay, R. N., Babcock, D., Dawson, T. M., Dewey, R. B., Foroud, T., German, D., Huang, X., Petyuk, V., Potashkin, J. A., Saunders-Pullman, R., Sutherland, M., Walt, D. R., West, A. B., Zhang, J., Chen-Plotkin, A., Scherzer, C. R., Vaillancourt, D. E., & Rosenthal, L. S.
- Venue
- Biomarkers in Medicine
- Publisher
- Informa UK Limited
- Published
- 2017-05
- Volume
- 11
- Issue
- 6
- Pages
- 451-473
- ISSN
- 1752-0363 (ISSN-L)
- 1752-0371
- OpenAlex
- W2692583471
- Cited by
- 64
- References
- 13
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Parkinson’s Disease Biomarkers: Perspective from the NINDS Parkinson’s Disease Biomarkers Program. https://app.cochat.ai/papers/10.2217/bmm-2016-0370
- The paper
- Gwinn, K., David, K. K., Swanson-Fischer, C., Albin, R., Hillaire-Clarke, C. S., Sieber, B.-A., Lungu, C., Bowman, F. D., Alcalay, R. N., Babcock, D., Dawson, T. M., Dewey, R. B., Foroud, T., German, D., Huang, X., Petyuk, V., Potashkin, J. A., Saunders-Pullman, R., Sutherland, M., . . . Rosenthal, L. S. (2017). Parkinson’s Disease Biomarkers: Perspective from the NINDS Parkinson’s Disease Biomarkers Program. Biomarkers in Medicine. https://doi.org/10.2217/bmm-2016-0370
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.